Internal Medicine

Influenza vaccination is especially crucial among children and adolescents with chronic medical conditions that put them at high risk for severe outcomes.

The US disproportionately arrests individuals with mental illness, and relies on police officers to respond to health crises. Practical, preventive clinical measures need to help stop the cycle.

The new analysis on the screening tool in primary care patients with COPD highlights the need for further research to optimize CAPTURE's performance and impact on clinical outcomes.

New data show the FDA's rationale for approving drugs with unmet efficacy end points in pivotal trials has been inconsistent since at least 2018.

PET scanning, in particular, has provided advancement in the diagnosis process, which has offered a new perspective on cardiac sarcoidosis for clinicians.

Amid a blood shortage and continued stigmatization of HIV risk, it's hard to feel good about the FDA's delayed decision—though good may still come of it.

The sBLA for lanadelumab permits its use as a prophylaxis in children as young as 2 years old with the rare condition.

In recognition of Go Red for Women Day on February 3, this feature shines a spotlight on the hurdles faced by women in cardiology and offers perspective on the battle for gender-based equity in medicine from the perspective of a pair of female leaders.

Dr. Ian Flinn says many patients opt for treatment with Bruton's tyrosine kinase (BTK) over combination therapy.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

The monoclonal antibody serves as the first and only therapy for treating hemolysis in adults with cold agglutinin disease, an extremely rare condition.

An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.

After addressing a 2021 CRL, Verrica Pharmaceuticals vies for the agent to become the first drug approved to treat the common skin infection.

A new study from clinicians in the VA Boston Healthcare System provides an overview of the impact the COVID-19 pandemic has had on racial disparities in wait times for new cardiology and orthopedic specialist consultations.

Clinician awareness is imperative with this comorbidity because overestimated asthma severity often results in over-treatment, according to investigators.

Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.

New data show patients who receive referred specialist care from a physician who went to medical school or other certification programs with their primary provider report better survey scores.

Qualitative interview analysis show male department chairs commonly witness discrimination against their female peers—yet they often are silent for a litany of reasons.

Promising results from the IMerge phase 3 clinical trial met the primary and secondary endpoints in the investigation of imetelstat, a novel telomerase inhibitor developed for hematologic malignancies.

Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.

The FDA's plans to expedite and expand regulatory pathways has resulted in a novel drug development boom since 2017. The commissioner discusses the details of their strategy.